What’s New in 2017: Expectations vs. reality of the Pilot Program one year later How to achieve compliance synergies in process and controls: Anti-corruption vs. AML , trade and antitrust risks Do’s And Don’ts When Choosing between Going Public (IPO) or Making Yourself “Acquirable” – How to Mitigate the Respective Risks Global corruption risk assessments: […]

A Forum for Emerging and Innovative Pharma, Biotech and Device Companies. The industry’s “go-to” event for innovative and emerging bio/pharmaceutical and medical device manufacturers ramps up for the most in-depth and impactful year yet. Backed by 8 years of high-quality content, this Congress continues to elevate the bar in compliance by convening the brightest minds […]